Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study.
10.23876/j.krcp.2017.36.1.48
- Author:
Chang Yun YOON
1
;
Misol LEE
;
Seung Up KIM
;
Hyunsun LIM
;
Tae Ik CHANG
;
Youn Kyung KEE
;
Seung Gyu HAN
;
In Mee HAN
;
Young Eun KWON
;
Kyoung Sook PARK
;
Mi Jung LEE
;
Jung Tak PARK
;
Seung Hyeok HAN
;
Sang Hoon AHN
;
Shin Wook KANG
;
Tae Hyun YOO
Author Information
1. Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea. yoosy0316@yuhs.ac
- Publication Type:Original Article
- Keywords:
Chronic kidney disease;
Hepatic steatosis;
Metabolic syndrome;
Transient elastography
- MeSH:
Alanine Transaminase;
Bilirubin;
Body Mass Index;
C-Reactive Protein;
Diabetes Mellitus;
Elasticity Imaging Techniques;
Fatty Liver*;
Glomerular Filtration Rate;
Humans;
Linear Models;
Logistic Models;
Odds Ratio;
Renal Insufficiency, Chronic*;
Serum Albumin;
Triglycerides
- From:Kidney Research and Clinical Practice
2017;36(1):48-57
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Hepatic steatosis measured with controlled attenuation parameter (CAP) using transient elastography predicts metabolic syndrome in the general population. We investigated whether CAP predicted metabolic syndrome in chronic kidney disease patients. METHODS: CAP was measured with transient elastography in 465 predialysis chronic kidney disease patients (mean age, 57.5 years). RESULTS: The median CAP value was 239 (202–274) dB/m. In 195 (41.9%) patients with metabolic syndrome, diabetes mellitus was more prevalent (105 [53.8%] vs. 71 [26.3%], P < 0.001), with significantly increased urine albumin-to-creatinine ratio (184 [38–706] vs. 56 [16–408] mg/g Cr, P = 0.003), high sensitivity C-reactive protein levels (5.4 [1.4–28.2] vs. 1.7 [0.6–9.9] mg/L, P < 0.001), and CAP (248 [210–302] vs. 226 [196–259] dB/m, P < 0.001). In multiple linear regression analysis, CAP was independently related to body mass index (β = 0.742, P < 0.001), triglyceride levels (β = 2.034, P < 0.001), estimated glomerular filtration rate (β = 0.316, P = 0.001), serum albumin (β = 1.386, P < 0.001), alanine aminotransferase (β = 0.064, P = 0.029), and total bilirubin (β = −0.881, P = 0.009). In multiple logistic regression analysis, increased CAP was independently associated with increased metabolic syndrome risk (per 10 dB/m increase; odds ratio, 1.093; 95% confidence interval, 1.009–1.183; P = 0.029) even after adjusting for multiple confounding factors. CONCLUSION: Increased CAP measured with transient elastography significantly correlated with and could predict increased metabolic syndrome risk in chronic kidney disease patients.
